UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

(Amendment No.)*

Arbutus Biopharma Corporation

(Name of Issuer)

Common Shares, without par value (Title of Class of Securities)

03879J100 (CUSIP Number)

N/A (Date of Event which Requires Filing of this Statement)

Check the appropriate box t	o designate the rule	pursuant to which	this Schedule is filed:

☑ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 03879J100					
1	NAMES OF REPORT	NAMES OF REPORTING PERSONS			
	Two Seas Capital LP				
2	CHECK THE APPRO (a) \square (b) \square	OPRIATE BOX IF A MEMBER OF A G	GROUP (SEE INSTRUCTIONS)		
3	SEC USE ONLY				
4	CITIZENSHIP OR PI	LACE OF ORGANIZATION			
	Delaware				
		5	SOLE VOTING POWER		
	NUMBER OF		9,503,103		
	SHARES BENEFICIALLY	6	SHARED VOTING POWER		
	OWNED BY		0		
	EACH REPORTING	7	SOLE DISPOSITIVE POWER		
	PERSON		9,503,103		
	WITH	8	SHARED DISPOSITIVE POWER		
			0		

9,503,103

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

П

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA, PN

⁹ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

^{*} Based on 167,695,247 Common Shares, without par value ("Common Shares"), of Arbutus Biopharma Corporation (the "Issuer") outstanding as of November 3, 2023, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission ("SEC") on November 7, 2023.

1 NAMES OF REPORTING PERSONS

	Two Seas Capital GP	LLC			
2	CHECK THE APPRO (a) \square (b) \square	THECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) \square (b) \square			
3	SEC USE ONLY				
4	CITIZENSHIP OR PI	LACE OF ORGANIZATIO	N		
	Delaware				
		5	SOLE VOTING POWER		
	NUMBER OF		9,503,103		
	SHARES	6	SHARED VOTING POWER		
	BENEFICIALLY		0		
	OWNED BY EACH	7	0 SOLE DISPOSITIVE POWER		
	REPORTING	,	SOLE DISTOSTITVE TOWER		
	PERSON		9,503,103		
	WITH	8	SHARED DISPOSITIVE POWER		
			0		
9	AGGREGATE AMO	UNT BENEFICIALLY OW	NED BY EACH REPORTING PERSON		
	9,503,103				
10		GREGATE AMOUNT IN R	OW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	DERCENT OF CLAS	S REPRESENTED BY AM	MOLINT IN DOW (9)		
11	TERCEIVI OF CEAS	5 KEI KESENTED DI AW	IOONT IN ROW (5)		
	5.7%*				
12	TYPE OF REPORTIN	NG PERSON (SEE INSTRU	JCTIONS)		
	OO, HC				
* D	laced on 167 COF 247 C	Common Chaves of the Issue	r outstanding as of November 3, 2023, as disclosed in the Issuer's Form 10-		
	filed with the SEC on		outstanding as of Proveniber 3, 2023, as disclosed in the Issuer's Folill 10-		

NAMES OF REPORTING PERSONS Sina Toussi CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □ SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION **United States** 5 **SOLE VOTING POWER** 9,503,103 NUMBER OF 6 SHARED VOTING POWER **SHARES BENEFICIALLY OWNED BY** SOLE DISPOSITIVE POWER **EACH** REPORTING **PERSON** 9,503,103 WITH 8 SHARED DISPOSITIVE POWER AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN, HC

^{*} Based on 167,695,247 Common Shares of the Issuer outstanding as of November 3, 2023, as disclosed in the Issuer's Form 10-Q filed with the SEC on November 7, 2023.

Item 1(a) Name of Issuer:

Arbutus Biopharma Corporation (the "Issuer")

Item 1(b) Address of Issuer's Principal Executive Offices:

701 Veterans Circle Warminster, PA 18974

Item 2(a) Name of Person Filing:

The Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

- i) Two Seas Capital LP ("TSC");
- ii) Two Seas Capital GP LLC ("TSC GP"); and
- iii) Sina Toussi.

This statement relates to Common Shares (as defined in Item 2(d) below) held by Two Seas Global (Master) Fund LP (the "Global Fund") and Two Seas LNP Opportunities (Master) Fund LP (the "Opportunities Fund", and together with the Global Fund, the "Funds"). The principal business of TSC is providing investment advice as a registered investment adviser and serving as investment manager to the Funds and other advisory clients. As such, TSC has been granted investment discretion over portfolio investments, including the Common Shares, held by or for the account of the Funds, including the Funds' voting and discretionary decisions. TSC GP serves as general partner of TSC. Sina Toussi serves as the Chief Investment Officer of TSC and Managing Member of TSC GP.

Item 2(b) Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each of the Reporting Persons is 32 Elm Place, 3rd Floor, Rye, New York 10580.

Item 2(c) Citizenship:

- i) Two Seas Capital LP is a Delaware limited partnership;
- ii) Two Seas Capital GP LLC is a Delaware limited liability company; and
- iii) Sina Toussi is a United States citizen.

Item 2(d) Title of Class of Securities:

Common Shares, without par value (the "Common Shares")

Item 2(e) CUSIP No.:

03879J100

		a:
(a)		Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
(b)		Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
(c)		Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
(d)		Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	X	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	X	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
(i)		A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)		A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)		Group, in accordance with §240.13d-1(b)(1)(ii)(K).
		If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.
Iter	n 4	Ownership:
TSO	C - 9	Amount beneficially owned: 0,503,103 Common Shares P - 9,503,103 Common Shares oussi - 9,503,103 Common Shares
(b) TSO	C - 5 C G l	Percent of class: 5.7% P - 5.7% oussi - 5.7%
	110	
(c)		Number of shares as to which TSC has: (i) Sole power to vote or to direct the vote: 9,503,103
		(ii) Shared power to vote or to direct the vote: 0
		(iii) Sole power to dispose or to direct the disposition of: 9,503,103
		(iv) Shared power to dispose or to direct the disposition of: 0
Nur	nbe	r of shares as to which TSC GP has:
		(i) Sole power to vote or to direct the vote: 9,503,103
		(ii) Shared power to vote or to direct the vote: 0
		(iii) Sole power to dispose or to direct the disposition of: 9,503,103
		(iv) Shared power to dispose or to direct the disposition of: 0
Nur	nbe	r of shares as to which Sina Toussi has:
		(i) Sole power to vote or to direct the vote: 9,503,103
		(ii) Shared power to vote or to direct the vote: 0
		(iii) Sole power to dispose or to direct the disposition of: 9,503,103
		(iv) Shared power to dispose or to direct the disposition of: 0

If this statement is filed pursuant to §§ 240 13d-1(b), or 240 13d-2(b) or (c), check whether the person filing is

Item 3

The Common Shares reported for Item 4 total 9,503,103, of which 4,886,991 are held by the Global Fund and 4,616,112 are held by the Opportunities Fund. TSC may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as investment adviser of the Funds. TSC GP may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as general partner of TSC. Sina Toussi may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through his capacity as Managing Member of TSC GP.

The percentages reported for Item 4(b) are calculated based on a total of 167,695,247 Common Shares outstanding on November 3, 2023, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

Item 5 Ownership of Five Percent or Less of a Class:

This Item 5 is not applicable.

Item 6 Ownership of More Than Five Percent on Behalf of Another Person:

See disclosure in Item 4, which is incorporated by reference herein.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

See disclosure in Item 2, which is incorporated by reference herein.

Item 8 Identification and Classification of Members of the Group:

This Item 8 is not applicable.

Item 9 Notice of Dissolution of Group:

This Item 9 is not applicable.

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: November 21, 2023

Two Seas Capital LP

By Two Seas Capital GP LLC, its General Partner

By: /s/ Sina Toussi

Sina Toussi

Managing Member

Dated: November 21, 2023

Two Seas Capital GP LLC

By: /s/ Sina Toussi

Sina Toussi

Managing Member

Dated: November 21, 2023

Sina Toussi

Managing Member

By: /s/ Sina Toussi

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the Common Shares, without par value, of Arbutus Biopharma Corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

EXECUTED as of this 21st day of November, 2023.

TWO SEAS CAPITAL LP

By: Two Seas Capital GP LLC, its general partner

By: /s/ Sina Toussi

Name: Sina Toussi

Title: Managing Member

TWO SEAS CAPITAL GP LLC

By: /s/ Sina Toussi

Name: Sina Toussi

Title: Managing Member

SINA TOUSSI

By: /s/ Sina Toussi